Ordinary Index Rebalancing in the Solactive Genomics Index | November 2019

In the ordinary rebalance the following composition will be implemented:

ADVERUM BIOTECHNOLOGIES INC
AGILENT TECHNOLOGIES INC
ALNYLAM PHARMACEUTICALS INC
ARROWHEAD PHARMACEUTICALS INC
AUDENTES THERAPEUTICS INC
BIOMARIN PHARMACEUTICAL INC
BLUEBIRD BIO INC
BLUEPRINT MEDICINES CORP
CELGENE CORP
CRISPR THERAPEUTICS AG
DICERNA PHARMACEUTICALS INC
EDITAS MEDICINE INC
FLUIDIGM CORP
GENOMIC HEALTH INC
GENSCRIPT BIOTECH CORP
GILEAD SCIENCES INC
HOMOLOGY MEDICINES INC
ILLUMINA INC
INTELLIA THERAPEUTICS INC
INVITAE CORP
NANOSTRING TECHNOLOGIES INC
NATERA INC
PACIFIC BIOSCIENCES OF CALIFORNIA INC
PROQR THERAPEUTICS NV
PTC THERAPEUTICS INC
QIAGEN NV
REGENXBIO INC
ROCKET PHARMACEUTICALS INC
SANGAMO THERAPEUTICS INC
SAREPTA THERAPEUTICS INC
SOLID BIOSCIENCES INC
SORRENTO THERAPEUTICS INC
SPARK THERAPEUTICS INC
ULTRAGENYX PHARMACEUTICAL INC
UNIQURE B.V.
VERACYTE INC
VERTEX PHARMACEUTICALS INC
VOYAGER THERAPEUTICS INC
WAVE LIFE SCIENCES PTE LTD
ZIOPHARM ONCOLOGY INC